The Effects of Lovaza® in Acute Myocardial Infarction (OmegaMI)

This study has been terminated.
(Only 5 individuals were able to be recruited.)
Sponsor:
Collaborators:
GlaxoSmithKline
Albany College of Pharmacy and Health Sciences
Information provided by (Responsible Party):
Robert Block, University of Rochester
ClinicalTrials.gov Identifier:
NCT01155336
First received: June 25, 2010
Last updated: March 8, 2013
Last verified: March 2013
  Purpose

This study will explore the safety and effectiveness of adding Lovaza® to the therapeutic program utilized internationally for the treatment of individuals with acute coronary syndromes.


Condition Intervention Phase
Myocardial Infarction
Drug: Lovaza®
Drug: The placebo contained 1 gram of corn oil in each capsule.
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effects of Lovaza® on Platelet Function and Cardiac Electrophysiology in Acute Myocardial Infarction

Resource links provided by NLM:


Further study details as provided by University of Rochester:

Primary Outcome Measures:
  • Platelet Function [ Time Frame: 12 hours ] [ Designated as safety issue: No ]
    Platelet function will be measured with PFA-100 test which has been shown to correlate with an increased risk for cardiovascular events in several well conducted studies and in a meta-analysis. The PFA-100 measures the number of seconds required for a clot to form in whole blood which is passed through an aperture in a cartridge coated with epinephrine. It is meant to imitate clotting in human arteries.


Secondary Outcome Measures:
  • Cardiac Electrophysiology [ Time Frame: 1 week ] [ Designated as safety issue: No ]
    A 20-minute supine 12-lead Holter ECG will allow the quantification of a series of standard ECG parameters as well as provide insight into frequency-domain HRV parameters, QRS duration and morphology, using signal-averaged ECG (SAECG), repolarization morphology, and variability utilizing specialized programs.


Enrollment: 4
Study Start Date: June 2010
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lovaza®
Lovaza® is a prescription grade EPA+DHA fish oil supplement. Four capsules (each containing 1 gram of fish oil) were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
Drug: Lovaza®
Lovaza® is prescription grade EPA+DHA fish oil supplement.
Other Name: Fish oil
Placebo Comparator: Corn Oil
The placebo contained 1 gram of corn oil in each capsule. Four capsules were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
Drug: The placebo contained 1 gram of corn oil in each capsule.
Placebo Pill
Other Name: Corn oil

Detailed Description:

Atherosclerotic cardiovascular disease is the cause for over 19 million deaths in the US annually with coronary artery disease accounting for most of this mortality burden.1 Despite major advances in the treatment of coronary heart disease patients, a large number of victims of the disease who are apparently healthy die suddenly without prior symptoms. For those who arrive alive at an emergency department, a benefit is accrued from an orchestrated program of live-saving therapeutics designed to preserve ischemic or infarcted myocardium and prevent ventricular arrhythmias. However, despite improvements in door-to-balloon (angioplasty) times in the past decade, reductions in in-hospital mortality have not materialized.2 Average 30-day mortality from ST elevation MI has been shown to be approximately 7% despite the modern aggressive approach of utilizing acute pharmacologic and percutaneous interventions as well as a comprehensive approach to risk factor modification.3 Antiplatelet agents including aspirin, clopidogrel, heparin, and IIb/IIIa inhibitors represent stalwart components of the acute coronary syndrome therapeutic treatment program. At the same time, the safety of combination antiplatelet agents used acutely and chronically in individuals with an acute coronary syndrome is concerning as bleeding complications can result in serious, life-threatening consequences.4 Studies have shown that patients treated with the combination of aspirin and clopidogrel have a small but significant increased risk of major and minor bleeding compared to each agent alone.4-6 In contrast, the use of fish oil in conjunction with aspirin and clopidogrel in patients with cardiovascular disease followed for an average of 33 months has been shown to have no significant effect on risk of major and minor bleeding compared to those on aspirin and clopidogrel alone, with a trend toward a reduced risk of minor bleeding in those taking fish oil.4 In Preliminary Data it is shown that a robust synergistic effect between Lovaza® and aspirin on the downregulation of platelet function may occur. These data suggest that the most potent omega-3 fatty acids found in fish oil (eicosapentaenoic acid {EPA} and docosahexaenoic acid {DHA}) act acutely to modulate a major contributor to the pathophysiology of acute coronary syndromes. This study will randomize 60 patients with ST elevation myocardial infarction to treatment with Lovaza® or placebo and measure the differences in platelet function and electrophysiologic parameters between treatment arms during their acute hospitalization and 1 week after discharge.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Acute myocardial infarction documented by at least 2 of the following:

    1. Typical symptoms
    2. Abnormal levels of cardiac biomarkers (troponin I or T or CK-MB mass) with at least one determination > 99th percentile or ULN for the laboratory
    3. ECG findings diagnostic of myocardial infarction based on the American College of Cardiology criteria.
  • Status-post urgent or emergent PCI
  • Have a Thrombolysis In Myocardial Infarction (TIMI) flow grade = 3 (complete perfusion) post PCI.
  • Have the capacity for informed consent (e.g. without significant dementia or sedation from medication)
  • Ingested 325 mg of chewed aspirin as part of the acute coronary syndrome treatment protocol.

Exclusion Criteria:

  • No informed consent
  • Daily aspirin use prior to index hospitalization
  • Known prior myocardial infarction
  • Known pregnancy
  • Known allergy to fish, fish oil, or aspirin
  • Known active internal or non-superficial bleeding, known bleeding disorder, coagulation defect, or thrombocytopenia
  • Thrombolysis in the past 12 hours
  • Treatment with a IIbIIIa inhibitor during index hospitalization
  • Cardiogenic shock or symptomatic hypotension or sitting SBP < 95 mmHg
  • Severe uncontrolled hypertension (≥180/110) or hypertensive retinopathy
  • A history of major surgery, trauma, retinal hemorrhage, significant gastrointestinal (not hemorrhoidal) or genitourinary bleeding in the past 6 weeks
  • A history of cerebrovascular attack within two years, or cerebrovascular attack with a significant residual neurological deficit
  • A known arteriovenous malformation or aneurysm
  • Severe liver insufficiency (ALT ≥ 3 times normal)
  • Renal insufficiency requiring dialysis
  • A known diagnosis of vasculitis
  • Participation in another clinical study
  • History of malignancy, except subjects who have been disease-free for greater than 10 years, or whose only malignancy has been basal or squamous cell skin carcinoma
  • Oral contraceptive use
  • Daily use of NSAIDs
  • History of drug or alcohol abuse, or current weekly alcohol consumption >14 units/week (1 unit = 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 shot of alcohol)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01155336

Locations
United States, New York
University or Rochester
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
GlaxoSmithKline
Albany College of Pharmacy and Health Sciences
Investigators
Principal Investigator: Robert Block, MD, MPH University or Rochester
  More Information

No publications provided

Responsible Party: Robert Block, Assistant Professor, University of Rochester
ClinicalTrials.gov Identifier: NCT01155336     History of Changes
Other Study ID Numbers: LVZ114193
Study First Received: June 25, 2010
Results First Received: February 5, 2013
Last Updated: March 8, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of Rochester:
Acute Coronary Syndrome
Fish Oils
Platelet Function Tests
Cardiac Electrophysiology

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on August 21, 2014